Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck

Journal of Clinical Oncology

Volumn 27, Issue 27, 2009, Pages 4448-4453

  Haddad, Robert I ^a   Tishler, Roy B ^a   Norris, Charles ^a   Goguen, Laura ^a   Balboni, Tracy A ^a   Costello, Rosemary ^a   Wirth, Lori ^a   Lorch, Jochen ^a   Andreozzi, Britta ^a   Annino, Donald ^a   Posner, Marshall R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ACNE; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG SAFETY; ENTERITIS; FEMALE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAIL INFECTION; OROPHARYNX CARCINOMA; PARONYCHIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; TAXOIDS;

EID: 76749121924     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.1333     Document Type: Article

References (20)

1. Haddad RI, Shin DM: Recent advances in head and neck cancer. N Engl J Med 359:1143-1154, 2008
2. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003
3. Adelstein DJ, Li Y, Adams GL, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
4. Ang KK, Harris J, Garden AS, et al: Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14. J Clin Oncol 23:3008-3015, 2005
5. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991
6. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007
7. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007
8. Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three metaanalyses of updated individual data: MACH-NC Collaborative Group Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955, 2000
9. Domenge C, Hill C, Lefebvre JL, et al: Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma: French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 83:1594-1598, 2000
10. Haddad R, Norris C, Sulivan C, et al: Docetaxel, cisplatin and 5-fluorouracil based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: The Dana-Farber Cancer Institute experience. Cancer 97:412-418, 2003
11. Calais G, Pointreau Y, Alfonsi M, et al: Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer: Preliminary results of GORTEC 2000-01. J Clin Oncol 24:281s, 2006 (suppl; abstr 5506)
12. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
13. Vermorken JB, Trigo J, Hitt R, et al: Openlabel, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171-2177, 2007
14. Nakata E, Hunter N, Mason K, et al: C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys 59:1163-1173, 2004
15. Knecht R, Peters S, Solbach C, et al: EGFR antibody-supplemented TPE-chemotherapy: Preclinical investigations to a novel approach for head and neck cancer induction treatment. Anticancer Res 23:4789-4795, 2003
16. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
17. Vokes EE, Stenson K, Rosen FR, et al: Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 21:320-326, 2003
18. Kies MS, Garden AS, Holsinger C, et al: Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN). J Clin Oncol 24:285s, 2006 (suppl; abstr 5520)
19. Wanebo H, Ghebremichael M, Burtness B, et al: Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). J Clin Oncol 25: 302s, 2007 (suppl; abstr 6015)
20. Argiris AE, Gibson MK, Heron DE, et al: Phase II trial of neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (X), P, and E in locally advanced head and neck cancer (HNC). J Clin Oncol 26:316s, 2008 (suppl; abstr 6002)